Product Description
Mechanisms of Action: LT Antagonist, PDE Inhibitor, 5-LOX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: MediciNova
Company Location: Western America
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - MediciNova presented P2 Fatty Liver|Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease results on 2024-05-28 for Tipelukast
- Clinical Outcomes Reported - MediciNova presented P2 Non-alcoholic Fatty Liver Disease results on 2024-05-26 for Tipelukast
Highest Development Phases
Phase 2: Fatty Liver, Alcoholic|Hypertriglyceridemia|Non-alcoholic Fatty Liver Disease|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05464784 |
MN-001-NATG-202 | P2 |
Active, not recruiting |
Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|Type 2 Diabetes|Hypertriglyceridemia |
2026-12-31 |
50% |
2026-02-06 |
Primary Completion Date|Primary Endpoints|Treatments|Trial Status |